Entasis Therapeutics

Patent cliffs & loss of exclusivity

Small molecule anti-infectives

Company

Legal NameEntasis Therapeutics Holdings Inc.
Company Operating StatusActive
Contact Page URLhttps://www.entasistx.com/contact
Crunchbase URLhttps://www.crunchbase.com/organization/entasis-therapeutics
Full AddressBoston BioHub 35 Gatehouse Drive Waltham, MA USA 02451, USA
LinkedIn URLhttps://www.linkedin.com/company/6453563
Pitchbook URLhttps://pitchbook.com/profiles/company/119236-60
Previous NameEntasis Therapeutics Ltd

2 upcoming patent cliffs

DrugIngredientTypeCliff
  1. XACDURO (COPACKAGED)DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUMSmall mol.Nov 2035
  2. NUZOLVENCEZOLIFLODACINSmall mol.Dec 2035

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Not found